Aaron Gal analyst

Currently out of the existing stock ratings of Aaron Gal, 17 are a HOLD (43.59%), 22 are a BUY (56.41%).

Aaron Gal

Work Performance Price Targets & Ratings Chart

Analyst Aaron Gal, carries an average stock price target met ratio of 66.31% that have a potential upside of 20.56% achieved within 338 days. Previously, Aaron Gal worked at BERNSTEIN.

Aaron Gal’s has documented 78 price targets and ratings displayed on 12 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ABBV, AbbVie at 17-Oct-2024.

Wall Street Analyst Aaron Gal

Analyst best performing recommendations are on PFE (PFIZER).
The best stock recommendation documented was for PFE (PFIZER) at 11/2/2021. The price target of $44 was fulfilled within 3 days with a profit of $2.26 (5.41%) receiving and performance score of 18.05.

Average potential price target upside

BIIB Biogen PFE Pfizer REGN Regeneron Pharmaceuticals ABBV AbbVie GILD Gilead Sciences VTRS Viatris JAZZ Jazz Pharmaceuticals PLC TEVA Teva Pharma Industries Ltd ADR AMGN Amgen AGN Allergan plc MNTA Momenta Pharmaceuticals MYL Viatris

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold

Since 08-Jan-2026

$190

$2.38 (1.27%)

$199

3 days ago
(08-Jan-2026)

0/5 (0%)

$4 (2.15%)

Hold

Since 09-Dec-2024

$185

$-2.62 (-1.40%)

$180

4 days ago
(07-Jan-2026)

11/30 (36.67%)

$2.39 (1.31%)

200

Hold

Since 21-Oct-2021

$180

$-7.62 (-4.06%)

$125

4 days ago
(07-Jan-2026)

15/24 (62.5%)

$-2.61 (-1.43%)

208

Hold

Since 31-Oct-2024

$156

$-31.62 (-16.85%)

$149

30 days ago
(12-Dec-2025)

24/48 (50%)

$-16.5 (-9.57%)

266

Hold

Since 02-Aug-2024

$190

$2.38 (1.27%)

$140

1 months 1 days ago
(10-Dec-2025)

10/17 (58.82%)

$12.45 (7.01%)

223

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Aaron Gal?

On 2013

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?